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Engineered Chimeric Antigen Receptor (CAR) T-cell products have recently gained FDA and EMA approval and 
have demonstrated significant clinical efficacy against non-Hodgkin lymphoma and pediatric B-cell acute 
lymphoblastic leukemia. Despite the significant clinical and commercial progress these products represent, the 
high costs associated with patient-specific cell therapy manufacture needs to be addressed.  
 
The work presented here focuses on the growth of human primary T-cells and CAR-T cells across a range of 
commercially available expansion platforms, including stirred tank bioreactors, which although routinely 
employed for the production of biologics, are not commonly used for the manufacture of T-cells. Initial 
experimental studies were carried out in an automated ambr® 250 single use bioreactor system which has 
demonstrated significant success for suspension and adherent mammalian cell culture applications. Building on 
previous work undertaken in the group which developed a new bioreactor vessel for microcarrier culture, both 
the new and existing bioreactor vessels were characterized with respect to cell yield, fold expansion, viability, 
metabolite profile, T-cell subpopulations and kLa. The comparison between the two vessels was performed 
based on power per unit volume, kLa and stirring speed, ranging from 100 to 200 rpm, using at least 3 different 
donors per condition. 
 
T-Flask expansion of human primary T-cells was carried out as a static control and results were compared with 
the dynamic culture conditions (Figure 1). Results revealed a significantly higher fold expansion (p<0.05) in the 
ambr® 250 bioreactor at 200rpm (24.53 ± 1.50) compared to the static platform (16.38 ± 2.91). Moreover, the 
final product composition in terms of cell phenotype was not affected by the stirring regime. The dO2 
concentration, pH, and metabolite flux was measured throughout enabling for a better understanding of culture 
performance. 
 
Further studies have compared the growth and quality of human primary T and CAR-T cells across a range of 
different expansion platforms including a rocking-motion (WAVE®) bioreactor, G-Rex® cell culture device, gas-
permeable cell culture bags and the ambr15® microbioreactor. For each platform, the same culture conditions 
were used including cell source, medium formulation, and seeding density. The findings from this extensive 
comparability study will be presented, including an overview of the cell phenotype and quality. The findings will 
be used to identify the capability of each expansion platform for CAR-T process development and manufacture 
with the aim of developing a cost effective process for both autologous and allogeneic CAR-T cell therapies.  
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Figure 1 – Growth 
curves showing the 
viable cells density in 
two different vessels. 
The stirring speed range 
was varied between 100 
and 200 rpm. Media 
addition was performed 
on day 3, 4 and 5, while 
a 60% DO control was 
introduced from day 5 
until day 7. The cells 
were then harvested 
and stained for flow 
cytometry analysis. 
